Therapy of clinical stage IIA and IIB seminoma: a systematic review

[1] Gurney JK(2019)International trends in the incidence of testicular cancer: lessons from 35 years and 41 countries Eur Urol 76 615-623

[2] Florio AA(2015)Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009 World J Urol 33 623-631

[3] Znaor A(2018)Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS) Swiss Med Wkly 148 3752-3763

[4] Nigam M(2021)Management of germ cell tumours of the testis in adult patients. German clinical practice guideline part i: epidemiology, classification, diagnosis, prognosis, fertility preservation, and treatment recommendations for localized stages Urol Int 30 719-725

[5] Aschebrook-Kilfoy B(2021)Management of germ cell tumours of the testes in adult patients: german clinical practice guideline, part II—recommendations for the treatment of advanced, recurrent, and refractory disease and extragonadal and sex cord/stromal tumours and for the management of follow-up, toxicity, quality of life, palliative care, and supportive therapy Urol Int 6 808-814

[6] Shikanov S(2012)Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up J Clin Oncol 29 697-705

[7] Eggener S(2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 22 78-85

[8] Rothermundt C(2011)Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group J Clin Oncol 31 513-521

[9] Thurneysen C(2011)Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies Ann Oncol 41 e249-e258

[10] Cathomas R(2013)A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma Urol Oncol 28 606.e1-606.e7

[1] Gurney JK(2019)International trends in the incidence of testicular cancer: lessons from 35 years and 41 countries Eur Urol 76 615-623

[2] Florio AA(2015)Increasing incidence of testicular cancer in the United States and Europe between 1992 and 2009 World J Urol 33 623-631

[3] Znaor A(2018)Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS) Swiss Med Wkly 148 3752-3763

[4] Nigam M(2021)Management of germ cell tumours of the testis in adult patients. German clinical practice guideline part i: epidemiology, classification, diagnosis, prognosis, fertility preservation, and treatment recommendations for localized stages Urol Int 30 719-725

[5] Aschebrook-Kilfoy B(2021)Management of germ cell tumours of the testes in adult patients: german clinical practice guideline, part II—recommendations for the treatment of advanced, recurrent, and refractory disease and extragonadal and sex cord/stromal tumours and for the management of follow-up, toxicity, quality of life, palliative care, and supportive therapy Urol Int 6 808-814

[6] Shikanov S(2012)Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up J Clin Oncol 29 697-705

[7] Eggener S(2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement PLoS Med 22 78-85

[8] Rothermundt C(2011)Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish norwegian testicular cancer study group J Clin Oncol 31 513-521

[9] Thurneysen C(2011)Evolution in management of testicular seminoma: population-based outcomes with selective utilization of active therapies Ann Oncol 41 e249-e258

[10] Cathomas R(2013)A risk-adapted strategy of radiotherapy or cisplatin-based chemotherapy in stage II seminoma Urol Oncol 28 606.e1-606.e7